PAX5 and acute lymphoblastic leukemia: Moreover, JAK2 inhibitors efficiently block the constitutive kinase activity of PAX5‐JAK2 in transfected cells, suggesting that these inhibitors may be beneficial for the treatment of PAX5‐JAK2+ B‐ALL (Roberts et al, 2014; Schinnerl et al, 2015).